Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences, in collaboration with Merck Sharp & Dohme LLC, is conducting a Phase 3 clinical study titled ‘An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)’. The study aims to compare the effectiveness of pembrolizumab combined with sacituzumab govitecan against pembrolizumab alone in improving progression-free survival and overall survival in patients with metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression.
The interventions being tested are pembrolizumab, an immune checkpoint inhibitor, and sacituzumab govitecan, an antibody-drug conjugate. Pembrolizumab is administered alone or in combination with sacituzumab govitecan to evaluate their efficacy in treating NSCLC.
This interventional study uses a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. The study design ensures a clear comparison between the two treatment groups.
The study began on February 6, 2023, and is currently recruiting participants. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on August 19, 2025. These timelines are crucial for tracking the study’s progress and potential impact on treatment options.
The outcome of this study could significantly influence Gilead Sciences’ stock performance, as positive results may enhance their market position in the oncology sector. Investors should also consider the competitive landscape, where advancements in cancer treatments are rapidly evolving.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.